MIM
IOVA icon

Macroview Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Macroview Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-646
Closed -$2.94K – 734
2023
Q3 		$2.94K Buy
+646
New +$4.22K ﹤0.01% 522

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Macroview Investment Management's IOVA Position: Q4 2023 in Review

Macroview Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 646 shares — an estimated $2.94K sold.

Macroview Investment Management first reported a position in IOVA in Q3 2023 and held it in 1 quarter. The position peaked at $2.94K in Q3 2023. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • Macroview Investment Management reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Macroview Investment Management sold 646 Iovance Biotherapeutics shares in Q4 2023, an estimated $2.94K.
  • Macroview Investment Management first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 1 quarter.
  • Macroview Investment Management's Iovance Biotherapeutics position peaked at $2.94K in Q3 2023.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Macroview Investment Management's 13F filing for Q4 2023, filed 30 Jan 2024.